RARA CRAFT DATABASE for FDA Medical Devices
510(k)K210404

FDA DEVICE FACTS

Transpara 1.7.0

Screenpoint Medical B.V.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

AI/ML
DECISION DATEJune 2, 2021PRODUCT CODEQDQCLINICAL AREARadiology

Indications for use

Transpara is a software medical device for use in a healthcare facility or hospital with the following indications for use: Transpara software is intended for use as a concurrent reading aid for physicians interpreting screening full-field digital mammography exams and digital breast tomosynthesis exams from compatible FFDM and DBT systems, to identify regions suspicious for breast cancer and assess their likelihood of malignancy. Output of the device includes locations of calcification groups and soft-tissue regions, with scores indicating the likelihood that cancer is present, and an exam score indicating the likelihood that cancer is present in the exam. Patient management decisions should not be made solely on the basis of analysis by Transpara. Intended user population Intended users of Transpara are physicians qualified to read screening mammography exams and digital breast tomosynthesis exams. Intended patient population The device is intended to be used in the population of women undergoing screening mammography and digital breast tomosynthesis.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 11, 2026